Silverback Therapeutics Inc (SBTX) Stock
SBTX is no longer traded. Silverback Therapeutics Inc was delisted from the Nasdaq in November 2022.
Prices on this page are historical; the last trade was November 8, 2022 at $5.87.
Silverback Therapeutics Inc stock price history
SBTX final trading statistics
- Final close
- $5.87
- Final trading day
- Nov 8, 2022
- Market cap at delisting
- $211.66M
- Shares outstanding
- 36.06M
- Final 52-week range
- $2.80 – $8.97
- Avg. volume (final 3 mo.)
- 182,771
- All-time high (split-adj.)
- $60.41 · Mar 2021
- All-time low (split-adj.)
- $2.90 · May 2022
- Return since IPO
- -72.0%
- Beta
- —
- Book value / share
- $7.53
- Price / book
- 0.78
Silverback Therapeutics Inc annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $0.00 | -$89.5M | -$2.56 |
| FY2020 | $0.00 | -$32.9M | -$1.88 |
| FY2019 | $0.00 | -$24.0M | — |
| FY2018 | $0.00 | -$17.6M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Silverback Therapeutics Inc
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Silverback Therapeutics Inc stock FAQ
What happened to Silverback Therapeutics Inc stock?
Silverback Therapeutics Inc stock was delisted from the Nasdaq. Its final close was $5.87 on November 8, 2022.
Is SBTX stock still trading?
No. SBTX was delisted from the Nasdaq in November 2022 and no longer trades on a U.S. exchange.
What was the last price of SBTX stock?
SBTX closed at $5.87 on its final trading day, November 8, 2022, for a market value of about $211.66M.
What were Silverback Therapeutics Inc's revenue and earnings in its last full fiscal year?
Silverback Therapeutics Inc reported revenue of $0.00 and net income of -$89.5M in fiscal 2021, its last full year as a public company.
When did Silverback Therapeutics Inc go public?
Silverback Therapeutics Inc stock began trading on December 4, 2020.